URL | https://firstwordpharma.com/story/6062467 |
Source | FirstWord Pharma |
Date Published | 09/15/2025 |
Company/Division name | Emergent BioSolutions |
Parent company | Emergent Biosolutions |
Type of work | Manufacturing |
Reshoring category: | Reshoring |
Year reshoring announced: | 2025 |
Domestically, the work will be done: | In-house |
Capital investment ($): | 17 |
If relevant, work nearshored to: | - |
Industry(ies): | Chemicals |
Product(s) reshored | EMBEXA® (brincidofovir), a Smallpox Antiviral |
What domestic positive factors made reshoring more attractive? | Government Incentives, Impact on domestic economy |